Project Apollonia

---

Biomedical R&D in space is no longer a purely scientific pursuit—it is a high-potential driver of commercial innovation. As commercial spaceflight shifts from conceptual to operational, ensuring human health in extreme environments is both a biological imperative and a commercial opportunity. Our biomedical research and development (R&D) team offers targeted expertise in human space biology, radiation medicine, and the field of metabolomics—a powerful tool for precision health monitoring. By integrating molecular insights with translational studies - our research builds scalable, dual-use technologies that serve both astronauts in orbit and markets on Earth and informs the direction of future studies.

Extended human spaceflight introduces serious health risks, including:

• Cosmic radiation-induced DNA damage, cancer risk and neuro inflammation
• Immune system suppression
• Neurocognitive impairment and bone-muscle loss
• Microgravity alters muscle, bone, and immune function

Addressing these through countermeasures is not just essential for astronaut health—it’s a gateway to commercial applications in oncology, remote medicine, biotech, and insurance risk modeling.

Research Team